Cargando…

Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System

Purpose: Gastrointestinal perforation (GIP) is a fatal adverse event (AE). The AE of GIP induced by novel antineoplastic agents has attracted attention recently. We aimed to explore the AE signals of GIP related to novel antineoplastic agents comprehensively based on the FDA Adverse Event Reporting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Zicheng, Zhu, Haibin, Chen, Hongjun, Zhu, Lifei, Liao, Xiaolan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Science archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990630/ https://www.ncbi.nlm.nih.gov/pubmed/36942297 http://dx.doi.org/10.3389/jpps.2023.11235

Ejemplares similares

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database
por: Wang, Wei, et al.
Publicado: (2023)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
por: Liu, Lulu, et al.
Publicado: (2022)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches
por: Mohammed, Omima S., et al.
Publicado: (2023)

Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database
por: Guo, Mingxing, et al.
Publicado: (2022)

Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system
por: Al-Jazairi, Abdulrazaq S., et al.
Publicado: (2023)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
por: Zhai, Yinghong, et al.
Publicado: (2021)

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
por: Tanaka, Junko, et al.
Publicado: (2023)

COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database
por: Nakao, Hiroka, et al.
Publicado: (2023)

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System
por: Yang, Renjun, et al.
Publicado: (2022)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
por: Shu, Yamin, et al.
Publicado: (2022)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Pilot prescription survey of antineoplastic agents: real‐world data from veterinary teaching hospitals in Japan
por: Tanaka, Noriko, et al.
Publicado: (2019)

Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
por: Lopez-Martinez, Marina, et al.
Publicado: (2022)

Integration of real-world evidence from different data sources in health technology assessment
por: Graili, Pooyeh, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
por: Zhou, Zhi-Xuan, et al.
Publicado: (2022)

Thyroid dysfunction associated with iodine-contrast media: A real-world pharmacovigilance study based on the FDA adverse event reporting system
por: Huang, Lu, et al.
Publicado: (2023)

Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022
por: Huang, Haining, et al.
Publicado: (2023)

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
por: Kadoyama, Kaori, et al.
Publicado: (2011)

Influence of anticancer agents on sexual function: An in vivo study based on the US FDA Adverse Event Reporting System
por: Kataoka, Tomoya, et al.
Publicado: (2021)

Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
por: Lopez-Martinez, Marina, et al.
Publicado: (2023)

Antineoplastic and Immunosuppressive Agents—Part 1
por: Lajtha, L. G.
Publicado: (1975)

Extravasation of Antineoplastic Agents: Prevention and Treatments
por: Boschi, Rita, et al.
Publicado: (2012)

Antineoplastic Agents Targeting Sphingolipid Pathways
por: Kroll, Alexander, et al.
Publicado: (2020)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qpgr20e6obhgopa1vch5d1mna4